Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The firm pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The firm is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Follow-Up Questions
Who is the CEO of Lexicon Pharmaceuticals Inc?
Mr. Michael Exton is the Chief Executive Officer of Lexicon Pharmaceuticals Inc, joining the firm since 2024.
What is the price performance of LXRX stock?
The current price of LXRX is $1.33, it has increased 0.37% in the last trading day.
What are the primary business themes or industries for Lexicon Pharmaceuticals Inc?
Lexicon Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Lexicon Pharmaceuticals Inc market cap?
Lexicon Pharmaceuticals Inc's current market cap is $485.1M
Is Lexicon Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Lexicon Pharmaceuticals Inc, including 3 strong buy, 5 buy, 3 hold, 0 sell, and 3 strong sell
